The continuous glucose monitoring (CGM) market is poised for innovation with the anticipated launch of dual ketone sensors in 2026. These sensors aim to address diabetic ketoacidosis (DKA), a critical condition that accounts for $6.8 billion in U.S. hospital charges annually.
William Blair’s Brandon Vazquez, CFA, healthcare research analyst, explores the potential market impact of first-mover advantage with dual ketone sensors. With the type 1 diabetes market already 60% penetrated, CGM Deep Dive: Analysis of Ketone Sensor, Type 2 Non-Insulin Market and PCP/Endo Survey Results highlights the opportunity for targeted adoption and the competitive dynamics.
For more information on William Blair’s healthcare equity research, contact us or your William Blair representative.